Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance
International Urology and Nephrology · 02.11.2026
DOI: 10.1007/s11255-026-05467-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 02.11.2026. Verfasst von J Bradley Mason und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH NCI-SOAR.
Abstract (Originalsprache)
Background
Prostate Imaging after Focal Ablation (PI-FAB) and Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET) scoring systems have been recently developed to improve detection of post-ablation recurrence of clinically significant prostate cancer (csPCa). However, it is unknown how these two scoring systems compare in clinical practice.
Methods
Patients who underwent focal therapy (FT) for prostate cancer (PCa) and had post-FT MRI and biopsy were identified from a prospective registry. Post-FT MRIs were reviewed by two radiologists blinded to biopsy results using the PI-FAB and TARGET systems with scores of 3 and ≥ 4, respectively considered positive for csPCa. csPCa recurrence was defined as ≥ Gleason 3+4 (Grade Group [GG] 2) on biopsy. Diagnostic performance metrics, including sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV)/accuracy, were calculated. Area under the receiver operating characteristic curve (AUC) was generated using logistic regression and compared using DeLong’s tests. Inter-reader agreement was assessed with Cohen’s Kappa ( κ ).
Results
90 patients were eligible. Radiologist #1 showed PI-FAB sensitivity/specificity/PPV/NPV/accuracy/AUC of 67%/82%/54%/89%/78%/0.74, respectively; TARGET had values of 67%/79%/50%/88%/76%/0.73, respectively. Radiologist #2 showed PI-FAB sensitivity/specificity/PPV/NPV/accuracy/AUC of 62%/68%/42%/83%/66%/0.65, respectively; TARGET 62%/68%/42%/83%/66%/0.66. Logistic regression showed no difference in AUC for PI-FAB and TARGET (0.69; 95%CI 0.59–0.79 vs. 0.71; 95%CI 0.62–0.80, p = 0.696). Inter-reader agreement was fair for PI-FAB ( k = 0.35, p = 0.02) and moderate for TARGET ( k = 0.45, p < 0.01).
Conclusion
PI-FAB and TARGET scoring systems perform similarly in diagnostic performance, though inter-reader agreement is limited. Clinical parameters may be needed to fully assess csPCa recurrence after focal therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA.
- Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
- Department of Radiology, University of Chicago, Chicago, IL, USA.
- Health Studies, University of Chicago, Chicago, IL, USA.
- Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA. Abhinav.Sidana@bsd.uchicago.edu.
Förderung
- NIH NCI-SOAR
Zitieren
APA
Mason, J. B., Arias, J., Kalaycioglu, B., Oto, A., Ramirez, A. C., Han, S., Weiss, A., Megahed, H., Shalhav, A., Hamimi, A., Lee, S. M., & Sidana, A. (2026). Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05467-9
Vancouver
Mason JB, Arias J, Kalaycioglu B, Oto A, Ramirez AC, Han S, et al. Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05467-9
BibTeX
@article{Mason2026,
author = {Mason, J Bradley and Arias, Jorge and Kalaycioglu, Bora and Oto, Aytekin and Ramirez, Alejandro Calvillo and Han, Simon and Weiss, Alex and Megahed, Haidy and Shalhav, Arieh and Hamimi, Ahmed and Lee, Sang Mee and Sidana, Abhinav},
title = {Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05467-9}
}
EUVIMED